C-CAR036 CAR T-cell therapy (AbelZeta)

N/A

Report date: 2024/01/24 16:08:53

Base Information

Drug NameC-CAR036 CAR T-cell therapy (AbelZeta)

Drug Alias NameC-CAR036

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsClaudin 18 protein modulators

TargetsClaudin-18 splice variant 2

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesCellular Biomedicine (Shanghai) Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesCellular Biomedicine (Shanghai) Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A